1 Goldenberg RM, Berard LD, Cheng AY, Gilbert JD, Verma S, Woo VC, et al. SGLT2 Inhibitor–associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clinical Therapeutics. 2016;38(12):2654–2664.e1
2 John M, Gopinath D, Jagesh R. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives. Indian Journal of Endocrinology and Metabolism. 2016;20(1):22–31.
3 Swissmedic [Internet]. Suisse: DHPC – Risque d’acidocétose diabétique sous traitement avec les inhibiteurs SGLT2. Available from:
https://www.swissmedic.ch/marktueberwachung/00135/00157/02873/index.html?lang=fr
4 Schlienger JL, Halimi S. Les acidocétoses diabétiques atypiques. Médecine des Maladies Métaboliques. 2016;10(4):314–319.
5 Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology: position statement on the association of SLGT-2 inhibitors and diabetic ketoacidosis. Endocrine Practice. 2016;22(6):753–762.